CINCINNATI, OH--(Marketwire - June 02, 2011) -
Medpace, Inc. announces the addition of Mike Winegar as Vice President, Regulatory Affairs for Medpace Medical Device (MMD), a wholly owned subsidiary of Medpace, Inc. Medpace Medical Device
provides global pre-market and post-market clinical, regulatory, and quality solutions to the medical device industry.
Mike Winegar has more than twenty five years of experience in global regulatory affairs, regulatory compliance, quality assurance, and clinical research, with a particular emphasis on cardiovascular, neurovascular, and peripheral vascular technologies. Mike has held senior leadership positions with a number of large and small medical device companies.
"Mike Winegar is a highly valued research professional and seasoned industry expert in regulatory affairs, clinical research, and quality assurance," said Ryan Wilson, General Manager, MMD. "His extensive experience in the regulatory and clinical aspects of conducting medical device trials both within and outside of the United States, especially within the cardiac and vascular device arenas, further strengthens MMD's position as a top tier CRO for the medical device industry. The addition of Mike to the MMD team will allow us to offer deeper strategic solutions for global premarket and post-market clinical and regulatory challenges, including leading clients through changing European and US regulatory approval requirements."
ABOUT MEDPACE MEDICAL DEVICE
Medpace Medical Device (MMD) is a full service medical device CRO based in the Minneapolis, Minnesota area. MMD offers trial design, project management, site management, monitoring, biostatistics, regulatory support, and data management for companies with medical devices in the premarket and postmarket human clinical trial phase. MMD has the ability to conduct medical device clinical trials for small or large sponsors, in both the US and worldwide.
Visit Medpace Medical Device at: www.medpace.com/device
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.
Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.
With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.
Visit the Medpace website at: www.medpace.com